EndoStem Consortium

At a Glance
  • Status: Active Consortium
  • Year Launched: 2012
  • Initiating Organization: European Commission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Rare disease
  • Disease focus:
    Muscular Dystrophy
  • Location: Europe

Abstract

EndoStem is a partnership of 15 research and clinical teams from globally recognized academic centers, small biotech companies, and large pharmaceutical companies working together to develop new strategies aimed at stimulating stem cells that are resident in damaged tissue to repair it in situ. This approach is recognized as a promising approach to targeting stem cells for regenerative medicine because of the alignment with existing therapeutic development approaches used by large industry and recent advances in understanding the key barriers for tissue regeneration.

Mission

EndoStem’s aims are as follows:

Financing

EndoStem is co-financed by the European Commission via the Seventh Framework Programme.

Data Sharing

Ethics and regulatory control will be performed by three groups. The first is the preclinical/clinical trials team in Research Programs 1 and 6 as part of the day-to-day routine, which will follow national and international regulations and monitor the studies. The second is a regulatory management team, which includes members of Research Programs 1 and 6 and other experts from within the consortium who have experience in preclinical to clinical translation and trials. The third is a bioethics group, which will be independent, pluralist, and multidisciplinary. It will be composed of the ethics committees and designated representatives from each of the partners to ensure complete ethics and regulatory compliance. This group has two main aims: (a) define ethics guidelines for all experiments performed within the project and (b) interface the experimental workplan decision of the consortium with all the ethics committees of partner institutes. The ethics guidelines will harmonize existing national laws and will consider all European Union–derived recommendations.

Points of Contact

David Sassoon
EndoStem Coordinator
email: david.a.sassoon@gmail.com

Jonathan Dando
Consortium Manager
Dando Weiss and Colucci Limited
email: dandojonathan@hotmail.com

Revital Rattenbach
EndoStem RTD Coordinator
email: revital.rattenbach@gmail.com

Sponsors & Partners

Dando Weiss and Colucci Limited

E. Medea Scientific Institute

Ecole Polytechnique Fédérale de Lausanne

European Clinical Research Infrastructures Network

European Molecular Biology Laboratory (EMBL)

Fondazione Centro san Raffaele del Monte Tabor

Fondazione Istituto Firc Di Oncologia Molecolare

Fondazione Telethon

HMGBiotech

INSERM/UPMC Pitie Salpetriere Medical School

Institut Cochin

Institute of Genetics and BioPhysics

Italfarmaco

Liverpool John Moore’s University

Novartis

Pompeu Fabra University

Santhera Pharmaceuticals

University of Frankfurt


Last Updated: 04/14/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.